Payment overview · 2025
General Payments
$1,088.41
49 reported records · 17 companies
Healthcare provider profile · identity verified
Ira T Fine, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LUTHERVILLE, MD · NPI 1922079599
Verified facts
What the public records show
CMS Open Payments records show Ira T Fine, M.D. received $1,088.41 in general payments during 2025 across 49 reported records.
UCB, Inc. accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $228.70 | 21.0% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $157.98 | 14.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $92.80 | 8.5% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $81.86 | 7.5% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $81.24 | 7.5% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $66.63 | 6.1% | 4 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $60.87 | 5.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.06 | 5.5% | 3 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $48.74 | 4.5% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.53 | 3.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.03 | 2.9% | 1 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $29.89 | 2.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.97 | 2.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.67 | 2.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.12 | 2.1% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.96 | 2.1% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $18.36 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,088.41 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $228.70 | 13 | 2025 |
Source payment records
|
|||||
| ILARIS Normalized: ilaris |
Drug | Novartis Pharmaceuticals Corporation | $133.16 | 4 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $81.86 | 4 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $81.24 | 4 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $72.25 | 3 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $51.32 | 3 | 2025 |
Source payment records
|
|||||
| Kineret Normalized: kineret |
Drug | SOBI, INC | $48.74 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $36.12 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $34.53 | 1 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $31.03 | 1 | 2025 |
Source payment records
|
|||||
| HYRIMOZ Normalized: hyrimoz |
Biological | Sandoz Inc. | $29.89 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.97 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| Gazyva Normalized: gazyva |
Biological | Genentech USA, Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 12 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
39 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 322 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 206 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 53 |
| Lorazepam | Lorazepam | 172 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 47 |
| Prednisone | Prednisone | 156 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 148 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 33 |
| Losartan Potassium | Losartan Potassium | 125 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 25 |
| Valsartan | Valsartan | 98 | 27 |
| Furosemide | Furosemide | 85 | 20 |
| Meloxicam | Meloxicam | 84 | 27 |
| Trazodone Hcl | Trazodone Hcl | 82 | 19 |
| Lisinopril | Lisinopril | 80 | 25 |
| Allopurinol | Allopurinol | 69 | 19 |
| Simvastatin | Simvastatin | 67 | 18 |
| Synthroid | Levothyroxine Sodium | 66 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 19 |
| Eliquis | Apixaban | 61 | 12 |
| Azithromycin | Azithromycin | 59 | 43 |
| Bupropion Xl | Bupropion Hcl | 58 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 45 |
| Clonazepam | Clonazepam | 54 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 12 |
| Gabapentin | Gabapentin | 52 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 44 | 15 |
| Sertraline Hcl | Sertraline Hcl | 44 | 12 |
| Celecoxib | Celecoxib | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Alprazolam | Alprazolam | 40 | suppressed |
| Metformin Hcl | Metformin Hcl | 40 | suppressed |
| Irbesartan | Irbesartan | 39 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 39 | 39 |
| Tramadol Hcl | Tramadol Hcl | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 31 |
| Pregabalin | Pregabalin | 33 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 23 |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 20 |
| Carvedilol | Carvedilol | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Omeprazole | Omeprazole | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | 12 |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 13 |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Humira | Adalimumab | 13 | suppressed |
| Humira Pen | Adalimumab | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Actemra Actpen | Tocilizumab | 11 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,088.41 · 49 records | UCB, Inc. | Actemra, BENLYSTA, Bimzelx, CAPVAXIVE, CRYSVITA, EVENITY, Gazyva, HYRIMOZ, ILARIS, INSPIRE, Kineret, Korlym, ORENCIA, PURIFIED CORTROPHIN GEL, STRENSIQ, TAVNEOS, TREMFYA, VYNDAQEL, XELJANZ | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error